VIDEO: 90 Seconds With… Roby Zomer, MGC Pharmaceuticals
Got 90 seconds? Then listen to MGC Pharmaceuticals co-founder and managing director, Roby Zomer discuss the company’s latest research announcement.
MGC Pharmaceuticals (ASX:MXC) is a global biopharma company focused on developing and supplying high-quality phytotherapeutics and phytomedicines to patients in Europe, Australasia, and North America.
The company recently announced the results of a pre-clinical study examining the effectiveness of cannabinoids in the treatment of high grade brain tumours.
Stockhead gave MGC Pharmaceuticals co-founder and managing director Roby Zomer 90 seconds to expand on the significance of the study and what sets it apart from similarly focused research.
Have a good idea for our next 90 Seconds With… segment? Email us at [email protected].
UNLOCK INSIGHTS
Discover the untold stories of emerging ASX stocks.
Daily news and expert analysis, it's free to subscribe.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.